These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Risk/Benefit Communication: International Developments and Prospects for the Future]. Yamamoto M Yakugaku Zasshi; 2018; 138(3):299-306. PubMed ID: 29503420 [TBL] [Abstract][Full Text] [Related]
23. Drug safety monitoring: an international perspective. Edwards IR Ann Acad Med Singap; 1993 Jan; 22(1):107-10. PubMed ID: 8503628 [TBL] [Abstract][Full Text] [Related]
24. Drug safety in the European community. Sauer F Drug Saf; 1990; 5 Suppl 1():141-8. PubMed ID: 2182057 [TBL] [Abstract][Full Text] [Related]
25. Activities of the International Federation of Pharmaceutical Manufacturers Associations in world health. Cone M J Clin Epidemiol; 1991; 44 Suppl 2():45S-47S. PubMed ID: 2045841 [TBL] [Abstract][Full Text] [Related]
26. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. Onakpoya IJ; Heneghan CJ; Aronson JK BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061 [TBL] [Abstract][Full Text] [Related]
27. Drug hepatotoxicity from a regulatory perspective. Senior JR Clin Liver Dis; 2007 Aug; 11(3):507-24, vi. PubMed ID: 17723917 [TBL] [Abstract][Full Text] [Related]
28. The role of the innovation-based pharmaceutical industry in international drug information communication. Hoff LC Drug Inf J; 1983; 17(4):271-6. PubMed ID: 10265100 [TBL] [Abstract][Full Text] [Related]
29. The use of essential drugs. Seventh report of the WHO Expert Committee. World Health Organ Tech Rep Ser; 1997; 867():1-74. PubMed ID: 9299932 [TBL] [Abstract][Full Text] [Related]
30. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization. O'Neill RT Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506 [TBL] [Abstract][Full Text] [Related]
31. Special section. The evaluation of drugs: an international perspective. Int J Technol Assess Health Care; 1986; 2(4):613-708. PubMed ID: 10280881 [No Abstract] [Full Text] [Related]
32. [Safe Use of Recent New Drugs-Current Status and Challenges]. Ohashi Y Yakugaku Zasshi; 2018; 138(2):177-183. PubMed ID: 29386431 [TBL] [Abstract][Full Text] [Related]
33. The mechanics of assembling an international drug dossier. Buday PV Drug Inf J; 1983; 17(3):133-8. PubMed ID: 10265093 [TBL] [Abstract][Full Text] [Related]
34. [Diagnostic kits in parasitology: which controls?]. Rossi P Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705 [TBL] [Abstract][Full Text] [Related]
35. Drug evaluation and registration in Hungary. Paál TL; Káldor A; Fäller K J Clin Pharmacol; 1988 Feb; 28(2):105-12. PubMed ID: 3360964 [TBL] [Abstract][Full Text] [Related]
36. [Pharmacists contribute to the safety of medicines]. Nishihara S Yakugaku Zasshi; 2011; 131(6):865-9. PubMed ID: 21628969 [TBL] [Abstract][Full Text] [Related]
37. [Consensus conference on definitions in drug monitoring]. Benichou C; Danan G Therapie; 1987; 42(4):347-50. PubMed ID: 3317982 [No Abstract] [Full Text] [Related]
38. [Post-marketing drug safety measures for the attainment of safer and more effective use of drug]. Kurokawa T Yakugaku Zasshi; 2011; 131(6):885-90. PubMed ID: 21628973 [TBL] [Abstract][Full Text] [Related]
39. Drug evaluation after marketing. Slone D; Shapiro S; Miettinen OS; Finkle WD; Stolley PD Ann Intern Med; 1979 Feb; 90(2):257-61. PubMed ID: 443660 [TBL] [Abstract][Full Text] [Related]
40. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe. Nicoll A; Ammon A; Amato Gauci A; Ciancio B; Zucs P; Devaux I; Plata F; Mazick A; Mølbak K; Asikainen T; Kramarz P Public Health; 2010 Jan; 124(1):14-23. PubMed ID: 20141821 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]